Completes $50M Asset Sale to Eli Lilly; Reports July Operating Loss of $11.17M in Bankruptcy
SGMOQ has more than doubled off its 52-week low of $0.03.
Summary
Sangamo Therapeutics completed the sale of key technology assets to Eli Lilly for $50 million in cash and filed its July Monthly Operating Report, showing an $11.17 million net loss.
Key Events · Legal and Risk Events · SGMOQ
-
Asset Sale to Eli Lilly Completed
The company completed the previously announced sale of its technology platforms, including AAV capsid engineering, zinc finger protein, Modular Integrase genome editing, and the prion disease program (ST-506), along with related intellectual property, to Eli Lilly and Company for $50 million in cash and the assumption of certain liabilities. This sale was finalized on September 4, 2026, following court approval on August 20, 2026.
-
July Monthly Operating Report Filed
Sangamo Therapeutics filed its Monthly Operating Report for July 2026, disclosing a net loss of approximately $11.17 million for the month. The report also indicated a cash balance of $16.91 million at the end of July and confirmed the incurrence of $18 million in DIP obligations under a replacement DIP facility during the reporting period.
Analysis · SGMOQ · Life Sciences
This filing marks a critical step in Sangamo Therapeutics' Chapter 11 bankruptcy proceedings by finalizing the sale of significant technology platforms and intellectual property to Eli Lilly for $50 million. While providing substantial cash, this is a liquidation event, underscoring the company's distressed state. The accompanying Monthly Operating Report for July provides a financial snapshot, revealing an $11.17 million net loss and detailing the $18 million in new DIP financing, which is crucial for ongoing operations during bankruptcy.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1819 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMOQ was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $66.7M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.